Steven D. Harr
2014 - Juno Therapeutics
In 2014, Steven D. Harr earned a total compensation of $3.8M as Chief Financial Officer and Head of Corporate Development at Juno Therapeutics.
Compensation breakdown
| Bonus | $100,200 |
|---|---|
| Non-Equity Incentive Plan | $99,800 |
| Option Awards | $731,250 |
| Salary | $283,333 |
| Stock Awards | $2,208,000 |
| Other | $408,423 |
| Total | $3,831,006 |
Harr received $2.2M in stock awards, accounting for 58% of the total pay in 2014.
Harr also received $100.2K in bonus, $99.8K in non-equity incentive plan, $731.3K in option awards, $283.3K in salary and $408.4K in other compensation.
Rankings
In 2014, Steven D. Harr's compensation ranked 2,241st out of 13,032 executives tracked by ExecPay. In other words, Harr earned more than 82.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,241 out of 13,032 | 83rd |
Division Manufacturing | 800 out of 4,965 | 84th |
Major group Chemicals And Allied Products | 252 out of 1,690 | 85th |
Industry group Drugs | 195 out of 1,369 | 86th |
Industry Biological Products, Except Diagnostic Substances | 31 out of 241 | 87th |
Source: SEC filing on April 21, 2017.
Harr's colleagues
We found two more compensation records of executives who worked with Steven D. Harr at Juno Therapeutics in 2014.
News
Sana Biotechnology Former Executive Vice President and President, Research and Development Douglas Williams receives $3M in 2023
April 26, 2024
Sana Biotechnology General Counsel Bernard Cassidy receives $4M in 2022
April 28, 2023
Sana Biotechnology Chief Medical Officer Sunil Agarwal receives $1.9M in 2021
April 26, 2022